Prostate Cancer Coverage from Every Angle

Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis

By: Andrew Goldstein
Posted: Wednesday, May 22, 2019

Charlotte Skriver, MSc, of the Danish Cancer Society Research Center, and colleagues did not find convincing evidence of an overall protective effect of postdiagnosis low-dose aspirin use on prostate cancer mortality, based on a nationwide study of patients with prostate cancer in Denmark published in Annals of Oncology. However, for extended exposure periods, their findings indicate a possible inverse association between low-dose aspirin use and prostate cancer mortality 5 years after cancer diagnosis.

The study followed 29,136 patients with prostate cancer, 24.6% of whom took low-dose aspirin within 1 year of being diagnosed. The researchers defined postdiagnosis low-dose aspirin use as two or more prescriptions filled after prostate cancer diagnosis and nonuse as fewer than two prescriptions filled. Aspirin use was assessed within 1 year for the main analysis and 5 or 7.5 years in the secondary analysis.

Compared with nonusers of aspirin, patients who took low-dose aspirin had a fully adjusted hazard ratio of 0.95 for prostate cancer mortality and a fully adjusted hazard ratio of 1.12 for other-cause mortality. In the 5-year assessment, aspirin use was associated with a 9% lower prostate cancer mortality and a 6% higher other-cause mortality. In the 7.5-year assessment, the prostate cancer mortality went down 16%, whereas other-cause mortality increased by 8%.

Although the study findings did not support an overall effect of postdiagnosis low-dose aspirin use on prostate cancer mortality, low-dose aspirin use might be inversely associated with prostate cancer mortality after 5 years from cancer diagnosis, the investigators proposed.

Disclosure: The study authors’ disclosure information may be found at

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.